Despite significant advances in the treatment of people with HCV infection, professional practice gaps remain that contribute to continued morbidity and mortality. While clinical trials provide an evidence base regarding which direct acting antivirals (DAAs) are most likely to be effective for treating various patients, many HCV clinicians have not integrated them into their clinical practice. To address this problem, we have developed a case-based CME program that explores and analyzes current HCV treatment standards of care, including when to start treatment, re-treatment, HCV/HBV co-infection, HCV and HCC complications, decompensated cirrhosis and acute HCV. Participants in this program will gain knowledge and skills that should lead to improved patient care.
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HCV infection.
Upon completion of the program, participants should be able to:
Release Date: June 15, 2018
Expiration Date: June 15, 2019
Estimated time to complete each Module: 30 minutes
Media: Web
David Bernstein, MD
Vice Chairman of Medicine
Chief, Hepatology and Sandra Atlas Bass Center for Liver Diseases
Professor of Medicine and Education
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California
Paul Martin, MD
Chief Divisions of Gastroenterology and Hepatology
University of Miami
Miami, Florida
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Module 1 (Treatment-Naïve):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Re-Treatment After Non-Response to First Line DAAs):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Acute HCV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (HCV/HBV Co-infection):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (HCV and HCC):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 6 (Decompensated Cirrhosis):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
David Bernstein, MD:
|
Paul Kwo, MD:
|
Paul Martin, MD:
|
Mark Sulkowski, MD:
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
There are no fees for participating and receiving CME/CE credit for this activity. During the period, June 15, 2018 through June 15, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13226. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
